China’s pharma industry saw a drop of 28.1% in overall deal activity during Q2 2019, when compared with the last four-quarter average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 23 deals worth $1.92bn were announced in Q2 2019, compared to the last four-quarter average of 32 deals.
Venture financing was the leading category in the quarter with 16 deals which accounted for 69.6% of all deals.
In second place was M&A with six deals, followed by private equity with one transactions, respectively accounting for 26.1% and 4.4% of overall deal activity in the country’s pharma industry during the quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading deal category in China’s pharma industry with total deals worth $1.48bn, while venture financing and private equity deals totalled $429.66m and $14.85m, respectively.
China pharma industry deals in Q2 2019: Top deals
The top five pharma deals accounted for 85.5% of the overall value during Q2 2019.
The combined value of the top five pharma industry deals stood at $1.64bn, against the overall value of $1.92bn recorded for the quarter. The top announced China pharma industry deal tracked by GlobalData in Q2 2019 was Cordlife Group’s $911.98m acquisition of Global Cord Blood.
In second place was the $375m asset transaction with Eli Lilly and by Eddingpharm and in third place was Deyi Capital, Gaoke Xinyi Capital, Gongqingcheng Hanren, Huaxin Century Investment Group, Loyal Valley Capital, Nanjing Gaoke Xinchuang Investment, Qianlong Capital, SDIC Unity Capital, Shiyu Capital Group and Yuansheng Venture Capital’s $170.83m venture financing of Allist Shanghai Pharmaceutical Technology.
The $108.55m acquisition of Chengdu List Pharmaceutical by Jinzhou Aohong Pharmaceutical and 3E Bioventures, Decheng Capital, Oriza Seed Venture Capital, SDIC Fund Management, Sherpa Healthcare Partners and South China Venture Capital’s venture financing of EpimAb Biotherapeutics for $74m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
